Puma Biotechnology (NASDAQ: PBYI)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.170 | -0.010 | 0.1600 | ||||
REV | 45.070M | 45.700M | 630.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Puma Biotechnology (NASDAQ: PBYI) through any online brokerage.
Other companies in Puma Biotechnology’s space includes: CytomX Therapeutics (NASDAQ:CTMX), Adverum Biotechnologies (NASDAQ:ADVM), Celcuity (NASDAQ:CELC), Atossa Therapeutics (NASDAQ:ATOS) and Humanigen (NASDAQ:HGEN).
The latest price target for Puma Biotechnology (NASDAQ: PBYI) was reported by HC Wainwright & Co. on Friday, May 6, 2022. The analyst firm set a price target for 12.00 expecting PBYI to rise to within 12 months (a possible 331.65% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Puma Biotechnology (NASDAQ: PBYI) is $2.78 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Puma Biotechnology.
Puma Biotechnology’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Puma Biotechnology.
Puma Biotechnology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.